NeutriSci Announces Pending Approval From Japanese Government for Distribution of CBD Products Through Naturally Splendid

VANCOUVER, BC–(Marketwired – November 06, 2017) – NeutriSci International Inc. (the “Company” or “NeutriSci”) (TSX VENTURE: NU) (OTCQB: NRXCF) (FRANKFURT: 1N9), the innovator and pioneer behind neuenergy^®, is pleased to announce that its partner in Japan and South Korea for Ambarii Corporation (“Ambarii”) CBD products, Naturally Splendid USA (“Naturally Splendid”), expects final approval imminently from the Japanese government for distribution of CBD products in Japan.

Naturally Splendid has contributed significant work towards the application process to launch CBD infused products into the Japanese market through an e-commerce campaign being managed by First Step Japan (“FSJ”). FSJ is a marketing and distribution company located in Tokyo with extensive expertise in the Japanese consumer market. Naturally Splendid’s Japanese specific website for this market will be activated immediately upon final approval.

Ambarii is a joint venture between NeutriSci and Lexaria Bioscience Corp. (“Lexaria”) that was formed to produce and commercialize a line of healthy, sugar-free, edible cannabinoid quick dissolving tablets combining NeutriSci’s proprietary pterostilbene tablet form factor and Lexaria’s patented palatability and absorption enhancing technology.

Mr. Glen Rehman, President of NeutriSci International, commented, “Naturally Splendid will be marketing Ambarii’s proprietary mouth-melt full spectrum hemp CBD tablets in Japan and South Korea. Initial samples incorporating Naturally Splendid’s HempOmega technology with Ambarii’s fast-acting and highly absorbent delivery mechanism are in the process of being evaluated and tested and we look forward to commencing distribution in these new markets.”

Lexaria, a drug delivery platform innovator, recently announced it has received a new Notice of Allowance from the United States Patent and Trademark Office (“USPTO”) for the use of its technology as a delivery platform for all cannabinoids including THC; fat soluble vitamins; non-steroidal anti-inflammatory pain medications (“NSAIDs”); and nicotine. Lexaria’s technology in Ambarii products will be a significant differentiator for Japanese consumers looking for high quality products.

On Behalf of the Board of Directors of

NEUTRISCI INTERNATIONAL INC.
Glen Rehman
President

About NeutriSci International Inc.

NeutriSci specializes in the innovation, production, and formulation of nutraceutical products. Established in 2009, NeutriSci’s is building sustainable sales models with Convenience, Chain Drug, and Mass Market and Supermarket retailers for neuenergy^®, the Company’s natural energy and focus supplement that has at its core, the beneficial effects of blueberries.

Neuenergy^® contains a unique patented combination of blueberries (pterostilbene) and naturally derived caffeine, and is a revolutionary energy tab designed to deliver enhanced focus and mental clarity with no sugar, no calories and no crash associated with typical energy products. To find out more about neuenergy^®, please visit www.getneuenergy.com.

With the recent formation of Ambarii, a joint venture partnership with Lexaria Bioscience Corp., NeutriSci is expanding its reach into the burgeoning cannabinoid industry.

For more information, please visit: www.neutrisci.com or www.ambariicorp.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.

Statements in this press release have not been evaluated by the Food and Drug Administration. Products or ingredients are not intended to diagnose, treat, cure, or prevent any disease.